Establishment Labs to Present at the Jefferies Healthcare Conference

2 years ago

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and…

SleepScore Labs Unveils Latest Findings From 14 New Studies at SLEEP 2022 Conference

2 years ago

Research leveraging SleepScore’s expansive data collection advances science of sleep health across wide variety of themes. CARLSBAD, Calif.--(BUSINESS WIRE)--SleepScore Labs,…

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

2 years ago

Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapyPhase 2…

Clover Provides Update on 2022 Corporate Milestones

2 years ago

-- Changxing manufacturing facility readiness and CMC activities impacted by COVID-19 outbreak in China - the facility is now expected…

Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting

2 years ago

Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well toleratedBOSTON and…

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

2 years ago

MAU868, a first-in-class monoclonal antibody, was well tolerated in kidney transplant recipients with BK viremiaData presented as oral late breaker…

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

2 years ago

Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with…

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

2 years ago

Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and…

Immune Therapeutics, Inc. Announces Expansion of its Board of Directors

2 years ago

ORLANDO, Fla, June 03, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the…

Cooper Wellness Strategies and Welld Health Announce Partnership

2 years ago

Scientific data collected to facilitate health outcomes reportingDALLAS, June 03, 2022 (GLOBE NEWSWIRE) -- Cooper Wellness Strategies, a Cooper Aerobics…